Business and Finance

Home » Business and Finance

Tjoapack and Photocure Sign Agreement

Global contract packaging organisation, Tjoapack, has signed a 5-year agreement with Photocure for the packaging of its proprietary bladder cancer detection products. Hexvix/Cysview is a drug that is selectively taken up by cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLC).  BLC with Hexvix/Cysview improves the detection of tumours and leads [...]

Catalent Completes $5.5 Million Phased Clinical Storage Expansion at Kansas City Campus

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has completed the second phase of a $5.5 million expansion programme at its Kansas City, Missouri facility, to increase the controlled-substance and controlled-temperature storage capabilities for its clinical supply business. This marks the conclusion [...]

Catalent Biologics and Valerius Biopharma to Collaborate on Manufacture of Specialty Biosimilars

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Valerius Biopharma AG, a Swiss biopharmaceutical company dedicated to providing interchangeable treatment options for high-priced orphan and non-orphan biologics, are to collaborate on the development and manufacture of Valerius’ biosimilar products. Under the [...]

IXICO: New Contract with Top 10 Pharmaceutical Company

IXICO plc, the digital technologies company serving neuroscience, has signed a new contract with a top 10 pharmaceutical company, further expanding its relationship with one  of its existing clients. The contract value is £1.0 million during a 3 year term, with study planning and site set-up activities starting in the next few months. IXICO will [...]

Tjoapack Invests in Blistering Capabilities

Global contract packaging organisation (CPO) Tjoapack has invested in its blistering capacity, adding a new line that will be equipped with late-stage customisation printing capabilities. Expected to be operational by the end of Q3 2018, the new line, at the company’s facility in Etten-Leur, Netherlands, will take its total number of blistering lines to eight. [...]

Humira Biosimilars Set to Launch in the EU This Year

Humira biosimilars will have significant uptake in the EU as they are anticipated to be priced 10-20% lower than the originator brand across the EU. This will be further facilitated by the quotas that healthcare authorities have in place for biosimilar prescription, says GlobalData a leading data and analytics company. One of the highest quotas [...]

Lonza to Invest in Portsmouth (NH, USA) Site, Including Mid-Scale Biologics

Lonza Pharma & Biotech has announced the investment in a new phase of development at their Portsmouth (NH, USA) site. The expansion will include mid-scale mammalian capacity and the addition of new cell-therapy suites. With this latest round of growth, Lonza Portsmouth confirms its position as a leading-house in biologics manufacturing and ensures capacity for [...]

Synpromics Awarded £1.9 Million Grant from Scottish Enterprise

Synpromics Ltd, the leader in gene control, been awarded a £1.9 million research and development grant from Scottish Enterprise. The funds will expand Synpromics’ world leading R&D programmes in gene regulation for cell and gene medicines. This grant is part of Synpromics’ ambitious £5.4 million R&D project that initially creates 11 new high-skilled jobs. Synpromics [...]

Phillips-Medisize Expands and Adds Drug Handling Capability at New Richmond Facility

Phillips-Medisize, a Molex company, has announced the completion of another significant expansion to the company’s New Richmond, Wisconsin medical facility. With this expansion, the New Richmond site will bring value-added capabilities in drug handling to serve its pharmaceutical customers with the complete manufacture of drug delivery devices and compliance to the FDA 21 CFR 210/211 [...]

CordenPharma Announces Commercial Oligonucleotide API Manufacturing Expansion in CordenPharma Colorado

CordenPharma is pleased to announce the expansion of new commercial oligonucleotide API manufacturing capabilities in our FDA-inspected CordenPharma Colorado (Boulder, CO, USA) facility. The expansion, which was completed in Q1 2018, will provide cGMP oligonucleotide manufacturing capacity up to 2 mol, with a significant increase in total commercial capacity up to 500 kg annually, making [...]